Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

Simple item page
dc.contributor.authorUlanova, Marinaen
dc.contributor.authorPoljak, Anneen
dc.contributor.authorWen, Weien
dc.contributor.authorBongers, Andreen
dc.contributor.authorGloag, Lucyen
dc.contributor.authorGooding, Justinen
dc.contributor.authorTilley, Richarden
dc.contributor.authorSachdev, Perminderen
dc.contributor.authorBraidy, Nadyen
dc.date.accessioned2025-06-25T16:34:16Z
dc.date.available2025-06-25T16:34:16Z
dc.date.issued2020en
dc.description.abstractNanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer’s disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: ‘Alzheimer’s disease’ AND ‘nanoparticles’ AND ‘Magnetic Resonance Imaging.’ 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.en
dc.description.sponsorshipM Ulanova is a recipient of the Australian Postgraduate Award PhD scholarship. N Braidy is a recipient of the Australian Research Council Discovery Early Career Award (DE170100628). N Braidy and P Sachdev acknowledge funding from Yulgibar/Dementia Australia. L Gloag, J Gooding and R Tilley acknowledge funding under the Australian Research Council Linkage grant (LP150101014). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.en
dc.description.statusPeer-revieweden
dc.format.extent19en
dc.identifier.issn1743-5889en
dc.identifier.otherPubMed:32141799en
dc.identifier.otherORCID:/0000-0001-7548-1521/work/172102542en
dc.identifier.scopus85082146856en
dc.identifier.urihttp://www.scopus.com/inward/record.url?scp=85082146856&partnerID=8YFLogxKen
dc.identifier.urihttps://hdl.handle.net/1885/733765028
dc.language.isoenen
dc.rightsPublisher Copyright: © 2020 Future Medicine Ltd.en
dc.sourceNanomedicineen
dc.subjectAlzheimer's diseaseen
dc.subjectcontrast agentsen
dc.subjectdiagnosisen
dc.subjectMRIen
dc.subjectnanoparticlesen
dc.titleNanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Reviewen
dc.typeJournal articleen
dspace.entity.typePublicationen
local.bibliographicCitation.lastpage743en
local.bibliographicCitation.startpage725en
local.contributor.affiliationUlanova, Marina; University of New South Walesen
local.contributor.affiliationPoljak, Anne; University of New South Walesen
local.contributor.affiliationWen, Wei; University of New South Walesen
local.contributor.affiliationBongers, Andre; University of New South Walesen
local.contributor.affiliationGloag, Lucy; University of New South Walesen
local.contributor.affiliationGooding, Justin; University of New South Walesen
local.contributor.affiliationTilley, Richard; University of New South Walesen
local.contributor.affiliationSachdev, Perminder; University of New South Walesen
local.contributor.affiliationBraidy, Nady; University of New South Walesen
local.identifier.citationvolume15en
local.identifier.doi10.2217/nnm-2019-0316en
local.identifier.pure3966a909-a047-42d9-9fcd-0c6cad61a3cfen
local.identifier.urlhttps://www.scopus.com/pages/publications/85082146856en
local.type.statusPublisheden

Downloads

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS